What The Study Did: Resarchers compared post-Ad26.COV2.S (Johnson & Johnson/Janssen) vaccination cerebral venous sinus thrombosis (CVST, a blood clot in the brain) rates with prepandemic rates to estimate postvaccination CVST risk. The rate of this rare adverse effect must be considered in the context of the effectiveness of the vaccine in preventing COVID-19.
Authors: Aneel A. Ashrani, M.D., M.S., of the Mayo Clinic in Rochester, Minnesota, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamainternmed.2021.6352)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/10.1001/jamainternmed.2021.6352?guestAccessKey=f6fff3e2-d1bf-4380-955b-4320910dbcaf&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=110121
Journal
JAMA Internal Medicine